By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Moderna Therapeutics, Inc. 

200 Tech Square

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-714-6500 Fax: 617-583-1998

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellular or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.

Our novel chemistry enables messenger RNA to elude the body’s innate immune response. Once delivered, stable messenger RNA is translated into active, native protein by cells’ natural, well-tuned machinery for protein production. To date, we have made great strides in advancing messenger RNA as a drug platform, and have screened more than 100 new chemistries. Our current formulation represents a 50-fold increase in in vivo protein expression over our first generation chemistry, even as we have exponentially reduced the cost associated with manufacturing our messenger RNA Therapeutics™. We have also developed a broad intellectual property estate including 200 patent applications with 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions.

Moderna plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients.

Based in Cambridge, Massachusetts, Moderna is privately held and was founded in 2010 by Flagship VentureLabs in association with leading scientists from Boston Children’s Hospital and Massachusetts Institute of Technology.

Key Statistics

Ownership: Private

Web Site: Moderna


Company News
Merck & Co. (MRK) And Moderna Announce Strategic Collaboration To Advance Novel Mrna-Based Personalized Cancer Vaccines With KEYTRUDA(Pembrolizumab) For The Treatment Of Multiple Types Of Cancer 6/29/2016 9:31:04 AM
Moderna Gets Upfront $200M Cash, Ties New Cancer Pact With Merck & Co. (MRK) 6/29/2016 7:20:54 AM
Moderna And Charles River Laboratories (CRL) Announce Strategic Collaboration To Scale Moderna’s Nonclinical Development Efforts For Novel mRNA Therapeutics 6/6/2016 8:19:33 AM
Moderna Announces Appointment Of Dr. Michael Watson As President Of Valera Pharmaceuticals (VLRX) 4/4/2016 11:22:40 AM
Moderna Appoints Saqib Islam As Chief Business Officer 3/28/2016 10:18:10 AM
Moderna Announces Transition To A Clinical Stage Company, Provides Business Update And Outlines 2016 Strategic Priorities 1/12/2016 12:15:46 PM
Moderna, Through Valera, Its Infectious Disease Venture, Announces Initial Grant Of Up To $20 Million To Advance mRNA-Based Antibody Combination To Help Prevent HIV Infection 1/12/2016 11:51:52 AM
Booming Moderna Eyes Six Human Trials in 2016, Inks Deals with AstraZeneca PLC (AZN), Merck & Co. (MRK) and Signed Huge Lease in Cambridge for R&D Growth 1/12/2016 5:47:12 AM
AstraZeneca PLC (AZN) And Moderna Announce New Collaboration To Co-Develop And Co-Commercialize Immuno-Oncology mRNA Therapeutics 1/11/2016 1:05:27 PM
Moderna Licenses New Vaccine Candidates Against A New Viral Target To Merck & Co. (MRK) 1/11/2016 1:01:42 PM